Functional genomic screening

From target selection to patient stratification.
Identify and characterize therapeutic targets and biomarkers.

Functional genomic screens enable modulation of hundreds or thousands of genes in a single experiment to identify genetic pathways, cellular processes, novel therapeutic targets, and to genetically profile existing or potential therapeutics. This information can be used to support a range of applications from cellular development, elucidate mechanisms of action, and through to  patient stratification or exploration of potential new treatment paradigms

With integrated solutions for CRISPR knockout, CRISPR activation, CRISPR inhibition, and RNAi technologies our screening portfolio provides you a complete functional genomic screening platform.  Using either cell lines or primary cell cultures, Horizon’s screening platform can perform pooled, arrayed and even single cell screens with our flexible library technologies and formats. Libraries can be used either alone, or in tandem, and coupled with a variety of assay readouts.

Functional genomic screening capabilities & benefits

Arrayed screening

Using synthetic CRISPR and siRNA reagents on a one-gene per well basis with complex assay readouts.

Pooled screening

Employing lentiviral CRISPRko/i/a approaches in highly multiplexed pooled screens.

Screening libraries

Flexibility to scale to your needs

Select from whole genome or gene family catalog CRISPR and RNAi libraries or create a custom library in pooled or arrayed format.

siRNA screening services

Benefit from rapid and efficient workflows.

Expanding your gene modulation options.

RNA-based immune cell screens

Screening services for primary human immune cells.

Address clinically relevant biological questions in vitro.

CRISPR knockout screening services

Probe gene function. Find drug targets. Stratify patients.

Ensuring library specificity with algorithm optimized guide RNA.
Custom services available for unique research projects.

Gene modulation technologies in the development of cell based therapies

Learn about the principles, strategies and experimental outcomes of CRISPR screening     

App note: Pooled phenotypic CRISPR screens

Read more about pooled CRISPR–Cas9 knock-out screens - valuable tools for new drug target identification

App note: Dual CRISPRi/a screens

Read about CRISPR screens for:

  • Drug mechanisms of action
  • Target identification and validation

CRISPRa screening

CRISPR activation offers transient gain-of-function screening using endogenous expression mechanisms.

CRISPRi screening

CRISPR interference screening offers transient loss-of-function screening with the accuracy of the CRISPR guide system.

Dual CRISPRi/a screening

Exploit the power of paired loss-of-function and gain-of-function screening.

Use of parallel CRISPRi and CRISPRa gene modulation to identify drug interactions with paired gene perturbation analysis.

App note: Whole-genome CRISPRa screening

In this application note, we present a human whole-genome CRISPRa platform and demonstrate its effectiveness in identifying resistance genes complementary to those identified through loss-of-function screening. The ability to enhance transcription by several orders of magnitude offers researchers the opportunity to explore resistance mechanisms based on a CRISPRa-driven gain-of-function platform. 

Single-cell CRISPR screening

Identify the genetic interactions that underlie a treatment response with pooled CRISPR screening followed by single cell analysis.

Functional genomic screening with CRISPR technologies

Learn about CRISPR screening and techniques

Review article

Read a recent insightful review article headlining in SLAS Discovery's March issue entitled 'CRISPR: A Screener's Guide'.

CRISPR screens in primary human T cells

Gain a better understanding of how immune cells function using functional genomic screens.

Podcast: CRISPR screens

Listen to the recent podcast hosted by GEN:

CRISPR Screens Speed Drug Discovery Efforts in Disease Intervention

CRISPR screening from target selection to patient stratification